Key result
Pre-PCI evolocumab cuts 72-hour TNF-α levels ~96% vs standard oral therapy in acute MI.
Why the study?
Does a single upstream dose of evolocumab reduce early inflammatory markers and lipid parameters in patients with acute MI undergoing PCI?
RCT (n=60)
Open-label
randomly assigned
No
Does a single upstream dose of evolocumab reduce early inflammatory markers and lipid parameters in patients with acute MI undergoing PCI?
Answers are grounded in this paper and cite their sources.
A single upstream dose of evolocumab before PCI in acute MI patients rapidly reduces TNF-alpha and atherogenic lipoproteins at 72 hours, suggesting early anti-inflammatory and lipid-lowering benefits.
Background: Early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) in patients with acute myocardial infarction (MI) may anticipate and maximize lipid-lowering benefit. Whether PCSK9 inhibition also exerts early anti-inflammatory effects in this setting remains unclear. This study aimed to evaluate the effects of early PCSK9-i administration on inflammatory markers and lipid parameters in patients with acute MI undergoing percutaneous coronary intervention (PCI). Methods: In this randomized, prospective, single-center, open-label trial, patients with acute MI undergoing PCI were randomly assigned to receive a single upstream 140 mg subcutaneous dose of evolocumab immediately before PCI, on top of oral lipid-lowering therapy (LLT) (n = 30), or oral LLT alone (control group; n = 30). Tumor necrosis factor-alpha (TNF-α), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] levels were measured at baseline and during the early post-intervention phase. Results: Baseline TNF-α values and lipid parameters were similar between the two groups. At 72 h after PCI, TNF-α levels were significantly lower in the evolocumab arm compared with controls (0.01 vs. 0.25 pg/mL; p = 0.025). Evolocumab was also associated with a greater relative reduction in LDL-C levels from baseline (−48% vs. −18%; p < 0.001) and apoB levels (−34% vs. −11%; p < 0.001). The proportion of patients achieving the LDL-C goal of <55 mg/dL at 72 h was higher in the evolocumab group than in controls (50% vs. 10%; p < 0.001). Lp(a) levels at 72 h were also lower with evolocumab (12 [10–33] vs. 28 [13.1–70] mg/dL; p = 0.032). Conclusions: In patients with acute MI undergoing PCI, upstream administration of a single evolocumab dose was associated with suppression of the early post-intervention increase in TNF-α levels, together with rapid reductions in LDL-C, apoB, and Lp(a). These findings suggest a potential modulation of the early inflammatory response by PCSK9 inhibition in addition to its lipid-lowering effects. Larger studies are needed to confirm these observations and to determine their clinical relevance.
No takes yet. Share an insight, caveat, or question.
Patti et al. (2026) conducted an RCT in Acute myocardial infarction (n=60). Evolocumab vs. Oral lipid-lowering therapy alone was evaluated on TNF-α levels at 72 hours (p=0.025). A single 140 mg dose of evolocumab before PCI in acute MI patients significantly reduced TNF-α levels at 72 hours compared to oral lipid-lowering therapy alone (0.01 vs 0.25 pg/mL; p=0.025).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: